June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Origins of myofibroblasts and functional analysis of miR-24 in subretinal fibrosis
Author Affiliations & Notes
  • Yinga Wu
    Cell and Molecular Biology, Tulane University, New Orleans, Louisiana, United States
  • Yao Tong
    Cell and Molecular Biology, Tulane University, New Orleans, Louisiana, United States
  • Katherine Byrnes
    Cell and Molecular Biology, Tulane University, New Orleans, Louisiana, United States
  • Qi Zhou
    Cell and Molecular Biology, Tulane University, New Orleans, Louisiana, United States
  • Jing Ma
    Cell and Molecular Biology, Tulane University, New Orleans, Louisiana, United States
  • Shusheng Wang
    Cell and Molecular Biology, Tulane University, New Orleans, Louisiana, United States
    Department of Ophthalmology, Tulane University, New Orleans, Louisiana, United States
  • Footnotes
    Commercial Relationships   Yinga Wu None; Yao Tong None; Katherine Byrnes None; Qi Zhou None; Jing Ma None; Shusheng Wang None
  • Footnotes
    Support  NIH grant 2R01EY021862-07A1
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2128. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yinga Wu, Yao Tong, Katherine Byrnes, Qi Zhou, Jing Ma, Shusheng Wang; Origins of myofibroblasts and functional analysis of miR-24 in subretinal fibrosis. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2128.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Subretinal fibrosis occurs in multiple retinal diseases, including wet Age-related macular degeneration (AMD) and proliferative vitreoretinopathy (PVR). Myofibroblast is a major cell type that contributes to fibrosis. However, origin of myofibroblast during subretinal fibrosis is still unknown. The purpose of the project is to determine the myofibroblast origins and to define the function of miR-24 in subretinal fibrosis.

Methods : Perostin (Postn)-Cre;R26-tdTomato and Postn-MCM;R26-DTA mice were used to label myofibroblast and test its role in laser-induced subretinal fibrosis. The contribution of specific cell lineages was confirmed using five cre-expressing mouse lines. MiR-24 function in epithelial-mesenchymal transition (EMT), endothelial-mesenchymal transition (EndMT) and fibrosis were examined by overexpression in ARPE-19 cells and HUVEC. Novel miR-24 target genes were confirmed by Western blot and luciferase assays. Nuclear translocation of MRTF-A was tested after TGF-β2 treatment. Functional study of miR-24 in vivo has been done using a modified PVR model and is ongoing using laser injury model.

Results : By genetic lineage tracing, Postn-Cre can exclusively label the myofibroblasts and its critical contribution was confirmed by DTA mediated specific cell depleting. RPE cells, ECs, pericytes, and macrophages were found to undergo EMT, EndMT, pericyte-myofibroblast transition and macrophage-mesenchymal transition (MMT), and contribute to myofibroblasts in a laser-induced subretinal fibrosis model. miR-24 overexpression repressed EMT and EndMT as shown by Western blot and immunostaining. LIMK2 was confirmed as target of miR-24 in RPE cells. This is consistent with repressed stress fiber formation, increased G-actin/F-actin ration, and blunted TGF-β-induced nuclear translocation of MRTF, a key gene involved in EMT, EndMT and fibrosis. SMAD3 was identified as a novel miR-24 target gene in human cells. In the in vivo PVR model, overexpression of miR-24 in the injected ARPE-19 cells suppressed PVR formation.

Conclusions : Myofibroblasts critically contribute to subretinal fibrosis. RPE cells, ECs, pericytes, and macrophages are the major contributors to myofibroblasts in laser-induced subretinal fibrosis. MiR-24 overexpression prevents EMT, EndMT and fibrosis by targeting TGF/SMAD3 and LIMK2/MTRF pathways. MiR-24 could be a potential therapeutic agent for treating fibrotic eye diseases.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×